Zacks Research Has Pessimistic Outlook of Neogen Q2 Earnings

Neogen Co. (NASDAQ:NEOG - Free Report) - Zacks Research lowered their Q2 2027 EPS estimates for Neogen in a report issued on Wednesday, June 4th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.12 for the quarter, down from their prior estimate of $0.13. The consensus estimate for Neogen's current full-year earnings is $0.38 per share.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). The firm had revenue of $221.00 million for the quarter, compared to the consensus estimate of $225.27 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The company's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.12 EPS.

NEOG has been the topic of a number of other reports. Guggenheim decreased their price objective on shares of Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Piper Sandler reduced their target price on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a report on Tuesday, April 22nd.

Neogen Price Performance

Shares of NASDAQ:NEOG opened at $5.21 on Monday. The firm has a 50 day moving average of $5.84 and a 200-day moving average of $9.35. Neogen has a 12 month low of $3.87 and a 12 month high of $18.58. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.13 billion, a PE ratio of -2.38 and a beta of 1.84.

Institutional Investors Weigh In On Neogen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Harbour Investments Inc. acquired a new stake in shares of Neogen during the fourth quarter valued at about $27,000. Versant Capital Management Inc raised its holdings in Neogen by 1,495.4% in the 1st quarter. Versant Capital Management Inc now owns 3,127 shares of the company's stock valued at $27,000 after buying an additional 2,931 shares during the last quarter. Blue Trust Inc. boosted its position in Neogen by 196.7% during the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company's stock worth $41,000 after buying an additional 2,233 shares during the period. Johnson Financial Group Inc. acquired a new stake in Neogen during the 4th quarter worth approximately $43,000. Finally, Covestor Ltd grew its holdings in Neogen by 41.4% during the 4th quarter. Covestor Ltd now owns 4,103 shares of the company's stock worth $50,000 after acquiring an additional 1,202 shares during the last quarter. Institutional investors own 96.73% of the company's stock.

Insiders Place Their Bets

In related news, Director James C. Borel bought 35,000 shares of the firm's stock in a transaction on Thursday, April 24th. The shares were purchased at an average price of $4.89 per share, with a total value of $171,150.00. Following the completion of the purchase, the director now owns 60,474 shares in the company, valued at $295,717.86. This represents a 137.39% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director James P. Tobin purchased 10,000 shares of the stock in a transaction dated Tuesday, April 22nd. The shares were bought at an average price of $4.73 per share, with a total value of $47,300.00. Following the completion of the acquisition, the director now directly owns 37,474 shares of the company's stock, valued at approximately $177,252.02. This represents a 36.40% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 83,500 shares of company stock valued at $431,525. 1.13% of the stock is currently owned by corporate insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.